STE

SterisNYSE · Health Care Equipment · Health Care

Previous close

209.90

Change

−0.38 / −0.18%

FinDog View

Bullish

52-Week Range

195.14 – 269.44

P/E (TTM)

25.5

Forward P/E

20.4

Based on consensus earnings for the next 12 months

Market Cap

$20.5B

−8.64%

S&P 500 −2.41% over same period

Volume / Avg Volume

640K / 618K

1.04× average

Price History

Closing price · USD1M 6M 1Y 5Y

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 39.51M 6M 1Y 5Y

Recent Earnings

Click to read the FinDog analysis

Period	Reported	Revenue	EPS Actual / Est.	Next-Day Move	Analysis
FY2027 Q1 Quarter ended 2026-06	2026-08-05	$1.5B	2.59 / 2.53	−0.40%	Read analysis →
FY2026 Q4 Quarter ended 2026-03	2026-05-11	$5.9B	2.83 / 2.88	+4.46%	Pending
FY2026 Q3 Quarter ended 2025-12	2026-02-04	$1.5B	2.53 / 2.56	−7.74%	Pending
FY2026 Q2 Quarter ended 2025-09	2025-11-05	$1.5B	2.47 / 2.37	+6.94%	Pending
FY2026 Q1 Quarter ended 2025-06	2025-08-06	$1.4B	2.34 / —	+6.79%	Pending
FY2025 Q4 Quarter ended 2025-03	2025-05-14	$5.5B	2.74 / —	+8.52%	Pending

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data

Valuation

P/E is at percentile 0 of its 5-year rangeCheap

5-year range 27.0 – 182.2 · Median 39.5

Last 4 quarters: $340M in buybacks + $247M in dividends, 2.87% of market cap combined

P/E (TTM)

25.5

P/B

2.8

P/S

3.4

Dividend Yield

1.02%

Earnings Reaction

Over the last 6 reports, the stock moved ±5.8% on average on the first trading day after, rising 4 times

Most recent −0.40%

Volatility & Correlation

1-year beta 0.45 · Correlation with S&P 500 0.23Low beta

Annualized volatility 25% vs. 13% for the S&P 500

Insider Trading

View all →

Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions

Buy 0 · $0.00MSell 1 · $0.96MNet selling $0.96M

08-12Sohi MohsenDirectorSell$0.96M4,058 shares · Avg price 235.78

Multi-Quarter Financial Trends

View all quarters →

Last 12 quarters · As reported by the company

Quarter	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Free Cash Flow ($B)	EPS
FY2027 Q1	1.49	+7.3%	45.8%	0.29	0.20	0.28	—
FY2026 Q4	1.59	+7.3%	43.9%	0.32	0.22	0.25	2.24
FY2026 Q3	1.50	+9.2%	43.8%	0.27	0.19	0.20	1.96
FY2026 Q2	1.46	+9.9%	44.2%	0.27	0.19	0.20	1.94
FY2026 Q1	1.39	+8.7%	45.1%	0.25	0.18	0.33	1.79
FY2025 Q4	1.48	+4.3%	43.3%	0.22	0.15	0.19	1.48
FY2025 Q3	1.37	+5.6%	44.5%	0.25	0.17	0.24	1.75
FY2025 Q2	1.33	+7.3%	43.6%	0.22	0.15	0.15	1.51
FY2025 Q1	1.28	+8.1%	44.7%	0.19	0.15	0.20	1.46
FY2024 Q4	1.42	+10.8%	41.1%	—	-0.00	0.16	-0.01
FY2024 Q3	1.30	+16.7%	43.2%	0.23	0.14	0.17	1.42
FY2024 Q2	1.24	+13.5%	44.1%	0.19	0.12	0.06	1.16

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →

Ticker	Company	Market Cap	P/E	Revenue YoY	Gross Margin	1M	View
STE	Steris	$20.5B	25.5	+7.3%	45.8%	−8.64%	Bullish
LLY	Lilly (Eli)	$1.07T	39.9	+47.7%	85.8%	−3.83%	Bullish	Compare
JNJ	Johnson & Johnson	$644B	30.6	+6.6%	68.2%	+1.87%	Bullish	Compare
ABBV	AbbVie	$464B	73.7	+10.2%	74.7%	+4.87%	Neutral	Compare
MRK	Merck & Co.	$358B	112.2	+5.1%	73.5%	+6.57%	Neutral	Compare
UNH	UnitedHealth Group	$337B	23.9	+0.4%	88.1%	−5.15%	Neutral	Compare
TMO	Thermo Fisher Scientific	$240B	34.4	+10.5%	—	+10.75%	Bullish	Compare
AMGN	Amgen	$203B	23.3	+9.5%	72.0%	−10.26%	Neutral	Compare
GILD	Gilead Sciences	$183B	—	+10.2%	79.8%	+6.31%	Neutral	Compare

The View in One Line

FY27Q1 revenue up 7%, gross margin 45.8%, adjusted EPS 2.59 beat expectations, full-year guidance reiterated, Bullish.

Updated 2026-09-16

View History

09-16Neutral → Bullish
FY27Q1 revenue up 7%, gross margin 45.8%, adjusted EPS 2.59 beat expectations, full-year guidance reiterated, Bullish.

Notable Institutional Holders

Citadel Advisors · Ken Griffin$85.1MAdded +268%
Renaissance Technologies$24.4M
Bridgewater Associates · Ray Dalio$2.1MReduced −12%

As of 2026-06-30

Key Events

08-06Management Change
Steris Adds Director Boulud to Audit and Compliance Committees
On July 31, 2026, Pierre Boulud was appointed to Steris' audit committee and compliance and technology committee; he was elected a director on May 5.Source ↗
08-06Governance
Steris Annual Meeting Completes Director Elections and Auditor Ratification
At the July 31, 2026 annual meeting, shareholders elected 9 directors and ratified Ernst & Young as auditor for fiscal 2027; the board size was reduced to 9.Source ↗
08-05Restructuring
STERIS Reports Quarterly Results and Announces Chemicals Business Integration Plan
On August 5, 2026, STERIS reported quarterly results for the period ended June 30 and announced the integration of its chemical manufacturing and distribution operations, expected to result in $55 million to $70 million in pre-tax restructuring charges.Source ↗
05-07Management Change
Director Breeden Retires, Boulud Joins Board
On May 1, 2026, Richard C. Breeden announced he would not stand for re-election; on May 5, the board appointed Pierre Boulud as a director, with compensation of $76,989 for his term.Source ↗
04-06Management Change
Former CFO Advisory Agreement Extended to 2027, Annual Salary Cut to $60,000
Steris amended its transition agreement with former CFO Michael J. Tokich, extending his senior financial advisor engagement to March 31, 2027, cutting his annual salary to $60,000, and eliminating health, dental and life benefits.Source ↗

Key Financial Trends

Quarterly Revenue ($B)1.5

Gross Margin45.8%

Free Cash Flow ($B)0.3